Table 2 Clinicopathological characteristic according SII, NLR, PLR and PNI
Characteristics | SII ≥ 660 n = 149 | SII < 660 n = 183 | p | NLR ≥ 3.57 n = 137 | NLR < 3.57 n = 195 | p | PLR ≥ 147 n = 153 | PLR < 147 n = 179 | p | PNI ≥ 52.95 n = 94 | PNI < 52.95 n = 238 | p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | Â | Â | 0.145 | Â | Â | 0.413 | Â | Â | 0.147 | Â | Â | 0.037 |
 < 60 | 67 (45%) | 97 (53%) |  | 64 (47%) | 100 (51%) |  | 69 (45%) | 95 (53%) |  | 55 (59%) | 109 (46%) |  |
 ≥ 60 | 82 (55%) | 86 (47%) |  | 73 (53%) | 95 (49%) |  | 84 (55%) | 84 (47%) |  | 39 (41%) | 129 (54%) |  |
Gender | Â | Â | 0.725 | Â | Â | 0.647 | Â | Â | 0.372 | Â | Â | 0.181 |
 Male | 94 (63%) | 112 (61%) |  | 87 (64%) | 119 (61%) |  | 91 (59%) | 115 (64%) |  | 53 (56%) | 153 (64%) |  |
 Female | 55 (37%) | 71 (39%) |  | 50 (36%) | 76 (39%) |  | 62 (41%) | 64 (36%) |  | 41 (44%) | 85 (36%) |  |
Smoking status | Â | Â | 0.239 | Â | Â | 0.006 | Â | Â | 0.996 | Â | Â | 0.448 |
 No | 58 (39%) | 83 (45%) |  | 46 (34%) | 95 (49%) |  | 65 (42%) | 76 (42%) |  | 43 (46%) | 98 (41%) |  |
 Yes | 91 (61%) | 100 (55%) |  | 91 (66%) | 100 (51%) |  | 88 (58%) | 103 (58%) |  | 51 (54%) | 140 (59%) |  |
ECOG PS | Â | Â | <Â 0.001 | Â | Â | 0.167 | Â | Â | 0.105 | Â | Â | 0.031 |
 0–1 | 127 (85%) | 177 (97%) |  | 122 (89%) | 182 (93%) |  | 136 (89%) | 168 (94%) |  | 91 (97%) | 213 (89%) |  |
 2 | 22 (15%) | 6 (3%) |  | 15 (11%) | 13 (7%) |  | 17 (11%) | 11 (6%) |  | 3 (3%) | 25 (11%) |  |
Histology | Â | Â | 0.508 | Â | Â | 0.863 | Â | Â | 0.778 | Â | Â | 0.384 |
 Adenocarcinoma | 74 (50%) | 80 (44%) |  | 64 (47%) | 90 (46%) |  | 74 (48%) | 80 (45%) |  | 38 (40%) | 116 (49%) |  |
 Squamous | 67 (45%) | 94 (51%) |  | 65 (47%) | 96 (49%) |  | 71 (46%) | 90 (50%) |  | 51 (54%) | 110 (46%) |  |
 Other histology | 8 (5%) | 9 (5%) |  | 8 (6%) | 9 (5%) |  | 8 (6%) | 9 (5%) |  | 5 (6%) | 12 (5%) |  |
T stage | Â | Â | <Â 0.001 | Â | Â | <Â 0.001 | Â | Â | 0.063 | Â | Â | 0.245 |
 T1–T2 | 58 (39%) | 123 (67%) |  | 52 (38%) | 129 (66%) |  | 75 (49%) | 106 (59%) |  | 56 (60%) | 125 (53%) |  |
 T3–T4 | 91 (61%) | 60 (33%) |  | 85 (62%) | 66 (34%) |  | 78 (51%) | 73 (41%) |  | 38 (40%) | 113 (47%) |  |
N stage | Â | Â | 0.108 | Â | Â | 0.211 | Â | Â | 0.084 | Â | Â | 0.014 |
 Negative | 7 (5%) | 17 (9%) |  | 7 (5%) | 17 (9%) |  | 7 (5%) | 17 (9%) |  | 12 (13%) | 12 (5%) |  |
 Positive | 142 (95%) | 166 (91%) |  | 130 (95%) | 178 91(%) |  | 146 (95%) | 162 (91%) |  | 82 (87%) | 226 (95%) |  |
Clinical stage | Â | Â | 0.019 | Â | Â | 0.035 | Â | Â | <Â 0.001 | Â | Â | 0.022 |
 III A | 78 (52%) | 119 (65%) |  | 72 (53%) | 125 (64%) |  | 74 (48%) | 123 (69%) |  | 65 (69%) | 132 (55%) |  |
 III B | 71 (48%) | 64 (35%) |  | 65 (47%) | 70 (36%) |  | 79 (52%) | 56 (31%) |  | 29 (31%) | 106 (45%) |  |
Response | Â | Â | 0.018 | Â | Â | 0.877 | Â | Â | 0.151 | Â | Â | 0.715 |
 CR + PR | 73 (62%) | 76 (77%) |  | 74 (69%) | 75 (68%) |  | 72 (64%) | 77 (73%) |  | 36 (67%) | 113 (69%) |  |
 SD + PD | 45 (38%) | 23 (23%) |  | 33 (31%) | 35 (32%) |  | 40 (36%) | 28 (27%) |  | 18 (33%) | 50 (31%) |  |